New Genomic Editing Methods Produce Better Disease Models From Patient-Derived iPSCs

NEW ROCHELLE, N.Y. - Sept. 8, 2014 - PRLog -- Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, kryan@liebertpub.com

New Genomic Editing Methods Produce Better Disease Models From Patient-Derived Induced Pluripotent Stem Cells

New Rochelle, NY—Highly valuable for modeling human diseases and discovering novel drugs and cell-based therapies, induced pluripotent stem cells (iPSCs) are created by reprogramming an adult cell from a patient to obtain patient-specific stem cells. Due to genetic variation, however, iPSCs may differ from a patient's diseased cells, and researchers are now applying new and emerging genomic editing tools to human disease modeling, as described in a comprehensive Review article published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until September 30, 2014 (http://www.liebertpub.com/scd).

In “Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells,” (http://online.liebertpub.com/doi/pdf/10.1089/scd.2014.0167) Ihor Lemischka, Huen Suk Kim, Jeffrey Bernitz, and Dung-Fang Lee, Icahn School of Medicine at Mount Sinai (New York, NY), provide a detailed overview of the development of patient-specific iPSCs for modeling a disease. The authors describe the many factors that need to be considered when generating an iPSC-based disease model comprised of cells that are genetically identical, and they discuss the advantages and limitations of the three leading genomic editing tools: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the most recent, the clustered regularly interspaced short palindromic repeat (CRISPR) system.

“As our appreciation of iPSCs as primarily therapeutic screens and disease models matures, we look to advanced gene editing tools to assist in appropriate experimental design. Ihor Lemischka and colleagues provide a much needed examination of the advantages and shortcomings of such techniques,” says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.

About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Complete tables of content and a free sample issue may be viewed on the Stem Cells and Development website (http://www.liebertpub.com/scd).

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).